10x Genomics (TXG) Competitors $10.58 -0.20 (-1.86%) As of 06/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TXG vs. MIR, ST, CAMT, TRNS, EYPT, ALNT, CTKB, LAB, AEHR, and SENSShould you be buying 10x Genomics stock or one of its competitors? The main competitors of 10x Genomics include Mirion Technologies (MIR), Sensata Technologies (ST), Camtek (CAMT), Transcat (TRNS), EyePoint Pharmaceuticals (EYPT), Allient (ALNT), Cytek Biosciences (CTKB), Standard BioTools (LAB), Aehr Test Systems (AEHR), and Senseonics (SENS). These companies are all part of the "measuring and control equipment" industry. 10x Genomics vs. Its Competitors Mirion Technologies Sensata Technologies Camtek Transcat EyePoint Pharmaceuticals Allient Cytek Biosciences Standard BioTools Aehr Test Systems Senseonics 10x Genomics (NASDAQ:TXG) and Mirion Technologies (NYSE:MIR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, risk, profitability, analyst recommendations, valuation and media sentiment. Which has more volatility and risk, TXG or MIR? 10x Genomics has a beta of 1.99, suggesting that its share price is 99% more volatile than the S&P 500. Comparatively, Mirion Technologies has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Do insiders & institutionals have more ownership in TXG or MIR? 84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 78.5% of Mirion Technologies shares are owned by institutional investors. 9.4% of 10x Genomics shares are owned by company insiders. Comparatively, 6.3% of Mirion Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has higher earnings & valuation, TXG or MIR? Mirion Technologies has higher revenue and earnings than 10x Genomics. Mirion Technologies is trading at a lower price-to-earnings ratio than 10x Genomics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio10x Genomics$624.66M2.09-$182.63M-$1.30-8.14Mirion Technologies$870.20M5.45-$36.10M-$0.06-341.00 Does the MarketBeat Community favor TXG or MIR? 10x Genomics received 47 more outperform votes than Mirion Technologies when rated by MarketBeat users. However, 86.36% of users gave Mirion Technologies an outperform vote while only 50.00% of users gave 10x Genomics an outperform vote. CompanyUnderperformOutperform10x GenomicsOutperform Votes6650.00% Underperform Votes6650.00% Mirion TechnologiesOutperform Votes1986.36% Underperform Votes313.64% Do analysts prefer TXG or MIR? 10x Genomics currently has a consensus price target of $15.81, indicating a potential upside of 49.41%. Mirion Technologies has a consensus price target of $18.75, indicating a potential downside of 8.36%. Given 10x Genomics' higher possible upside, analysts clearly believe 10x Genomics is more favorable than Mirion Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 10x Genomics 1 Sell rating(s) 8 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.38Mirion Technologies 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Does the media refer more to TXG or MIR? In the previous week, 10x Genomics had 1 more articles in the media than Mirion Technologies. MarketBeat recorded 6 mentions for 10x Genomics and 5 mentions for Mirion Technologies. Mirion Technologies' average media sentiment score of 0.31 beat 10x Genomics' score of 0.30 indicating that Mirion Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Mirion Technologies 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is TXG or MIR more profitable? Mirion Technologies has a net margin of -4.21% compared to 10x Genomics' net margin of -29.90%. Mirion Technologies' return on equity of 4.78% beat 10x Genomics' return on equity.Company Net Margins Return on Equity Return on Assets 10x Genomics-29.90% -25.40% -19.69% Mirion Technologies -4.21%4.78%2.81% SummaryMirion Technologies beats 10x Genomics on 11 of the 19 factors compared between the two stocks. Get 10x Genomics News Delivered to You Automatically Sign up to receive the latest news and ratings for TXG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TXG vs. The Competition Export to ExcelMetric10x GenomicsAnalytical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.30B$4.57B$5.61B$8.62BDividend YieldN/A0.55%5.28%4.17%P/E Ratio-6.9628.5927.1819.96Price / Sales2.094.02412.23157.63Price / CashN/A36.3438.2534.64Price / Book1.821.667.064.69Net Income-$182.63M-$84.30M$3.23B$248.14M7 Day Performance12.31%2.46%0.80%0.95%1 Month Performance9.64%9.88%9.71%5.74%1 Year Performance-46.35%-9.82%32.11%14.73% 10x Genomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TXG10x Genomics4.2454 of 5 stars$10.58-1.9%$15.81+49.4%-50.4%$1.30B$624.66M-6.961,240Analyst ForecastMIRMirion Technologies0.695 of 5 stars$20.49+3.0%$18.75-8.5%+100.6%$4.75B$870.20M-107.842,870Short Interest ↑STSensata Technologies4.8432 of 5 stars$27.79+2.8%$34.08+22.7%-27.5%$4.06B$3.84B33.0820,800CAMTCamtek3.9612 of 5 stars$74.44+1.3%$90.78+21.9%-36.4%$3.39B$450.86M30.76400Positive NewsAnalyst RevisionGap DownTRNSTranscat2.9606 of 5 stars$76.68-1.7%$114.00+48.7%-38.1%$714.50M$278.42M41.45920EYPTEyePoint Pharmaceuticals2.4524 of 5 stars$8.93-0.1%$25.38+184.2%-4.9%$614.48M$56.04M-4.47120Positive NewsAnalyst RevisionGap UpALNTAllient2.8188 of 5 stars$33.36+4.6%$31.00-7.1%+30.9%$564.75M$516.06M37.911,950Positive NewsCTKBCytek Biosciences2.3396 of 5 stars$3.56+3.5%$5.60+57.3%-45.6%$450.91M$197.05M-44.49500Positive NewsHigh Trading VolumeLABStandard BioTools2.7058 of 5 stars$1.08+1.9%$2.50+131.5%-54.9%$410.21M$169.69M-1.52620AEHRAehr Test Systems3.6075 of 5 stars$11.78+3.9%$25.00+112.2%-13.9%$350.70M$61.48M15.7190Positive NewsSENSSenseonics2.3665 of 5 stars$0.53+0.6%$1.55+192.5%+30.0%$346.73M$23.68M-4.0890Positive News Related Companies and Tools Related Companies Mirion Technologies Alternatives Sensata Technologies Alternatives Camtek Alternatives Transcat Alternatives EyePoint Pharmaceuticals Alternatives Allient Alternatives Cytek Biosciences Alternatives Standard BioTools Alternatives Aehr Test Systems Alternatives Senseonics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TXG) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 10x Genomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 10x Genomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
